Tag: Anika Therapeutics

Anika Announces Regulatory Approval for MONOVISC® in Australia
Extremities Regulatory

Anika Announces Regulatory Approval for MONOVISC® in Australia

October 16, 2017 BEDFORD, Mass.–(BUSINESS WIRE)–Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced that regulatory authorities in Australia granted approval to MONOVISC®, Anika’s single injection viscosupplement for the treatment of pain associated with osteoarthritis of all […]

Anika to Issue Third-Quarter 2017 Financial Results and Business Highlights on Wednesday, October 25
Financial

Anika to Issue Third-Quarter 2017 Financial Results and Business Highlights on Wednesday, October 25

October 11, 2017 BEDFORD, Mass.–(BUSINESS WIRE)–Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its third-quarter 2017 financial results after the close of the market on Wednesday, October 25, 2017 and to hold a conference call the next day, Thursday, October 26, 2017, at 9:00 a.m. ET […]

Anika Announces Appointment of Steven Chartier as Vice President of Regulatory and Clinical Affairs
Biologics

Anika Announces Appointment of Steven Chartier as Vice President of Regulatory and Clinical Affairs

August 28, 2017 BEDFORD, Mass.–(BUSINESS WIRE)–Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced the appointment of Steven Chartier as Vice President of Regulatory and Clinical Affairs. Mr. Chartier brings more than 25 years of operational expertise […]

Anika Announces Publication of Data Demonstrating the Efficacy and Safety of HYALOFAST® in Combination with Stem Cells for the Treatment of Cartilage Lesions on the Knee
Biologics Top Stories

Anika Announces Publication of Data Demonstrating the Efficacy and Safety of HYALOFAST® in Combination with Stem Cells for the Treatment of Cartilage Lesions on the Knee

August 07, 2017 BEDFORD, Mass.–(BUSINESS WIRE)–Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced the publication of data demonstrating that HYALOFAST®, a biodegradable HA-based scaffold, used in combination with autologous adult mesenchymal stem cells (MSCs), regardless of a […]

Anika Announces Appointment of Joseph Darling as President
Biologics Top Stories

Anika Announces Appointment of Joseph Darling as President

July 27, 2017 BEDFORD, Mass.–(BUSINESS WIRE)–Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced the appointment of Joseph Darling, an orthopedic and medical device veteran with broad commercial experience, to the role of President. For the past […]

Anika Reports Strong Second Quarter 2017 Financial Results
Financial

Anika Reports Strong Second Quarter 2017 Financial Results

July 26, 2017 BEDFORD, Mass.–(BUSINESS WIRE)–Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today reported financial results for the second quarter ended June 30, 2017, along with business progress in the period. “Anika delivered strong double-digit revenue and […]

Anika Announces Regulatory Approval for MONOVISC® in India
Regulatory

Anika Announces Regulatory Approval for MONOVISC® in India

July 24, 2017 BEDFORD, Mass.–(BUSINESS WIRE)–Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced that regulatory authorities in India granted approval to MONOVISC®, its single injection viscosupplement for the treatment of pain associated with osteoarthritis of all human […]

Anika Celebrates 25th Anniversary and Inaugurates Newly Expanded Global Manufacturing Facility
Biologics

Anika Celebrates 25th Anniversary and Inaugurates Newly Expanded Global Manufacturing Facility

May 23, 2017 08:30 AM Eastern Daylight Time BEDFORD, Mass.–(BUSINESS WIRE)–Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, is hosting a celebration today at its Bedford, Massachusetts headquarters to commemorate its 25th anniversary and inaugurate its […]

Anika Therapeutics Announces Decision to Proceed with CINGAL® Premarket Review Through FDA’s Center for Drug Evaluation and Research
Regulatory

Anika Therapeutics Announces Decision to Proceed with CINGAL® Premarket Review Through FDA’s Center for Drug Evaluation and Research

BEDFORD, Mass.–(BUSINESS WIRE)–Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid technology, today announced that the U.S. Food & Drug Administration’s (FDA) Office of Combination Products has assigned CINGAL® to the Center for Drug Evaluation and Research (CDER) as the […]

Anika Therapeutics Announces Health Canada Approval of CINGAL® for the Treatment of Pain Associated with Osteoarthritis of the Knee
Regulatory

Anika Therapeutics Announces Health Canada Approval of CINGAL® for the Treatment of Pain Associated with Osteoarthritis of the Knee

BEDFORD, Mass.–(BUSINESS WIRE)–Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced Health Canada approval of CINGAL® as a medical device to treat pain associated with osteoarthritis (OA) of the knee. CINGAL is the first and […]

Chess Game with Focus on the King
Recon

Anika Appoints Richard Hague to Role of Chief Commercial Officer

BEDFORD, Mass.–(BUSINESS WIRE)– Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, announced the appointment of Richard Hague as Chief Commercial Officer. Mr. Hague, who brings over three decades of commercial leadership experience in the life sciences sector, will report […]

Anika Therapeutics Reports Robust Financial Performance and Continued Progress on Key Fronts in Third Quarter of 2015
Financial

Anika Therapeutics Reports Robust Financial Performance and Continued Progress on Key Fronts in Third Quarter of 2015

BEDFORD, Mass.–(BUSINESS WIRE)–Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today reported financial results for the third quarter ended September 30, 2015, along with business progress in the period. “Our third quarter sales and profits were […]

Anika Therapeutics Delivers Solid Second Quarter 2015 Financial Results and Continued Pipeline Progress
Financial

Anika Therapeutics Delivers Solid Second Quarter 2015 Financial Results and Continued Pipeline Progress

BEDFORD, Mass.–(BUSINESS WIRE)–Anika Therapeutics, Inc. (NASDAQ: ANIK), a leader in products for tissue protection, healing, and repair based on hyaluronic acid (HA) technology, today reported financial results for the second quarter ended June 30, 2015, along with business progress in the period. “The solid results we delivered in the second […]

Anika Therapeutics Announces Positive Results from Follow-up Study Evaluating Safety of a Repeat Injection of CINGAL for Treatment of Osteoarthritis of the Knee
Extremities Top Stories

Anika Therapeutics Announces Positive Results from Follow-up Study Evaluating Safety of a Repeat Injection of CINGAL for Treatment of Osteoarthritis of the Knee

BEDFORD, Mass., Jul 09, 2015 (BUSINESS WIRE) — Anika Therapeutics, Inc., ANIK, +0.35% a leader in products for tissue protection, healing, and repair based on hyaluronic acid (HA) technology, today reported positive results from the CINGAL® 13-02 study evaluating the safety of a repeat injection of CINGAL for symptomatic relief of osteoarthritis (OA) of […]